Molecular test algorithms for breast tumours
Health and disease monitoring
Download 1.32 MBPeer reviewed scientific article
English
SCIENSANO
Authors
Aline Hébrant [2]; K Punie [3]; FP Duhoux [4]; C Colpaert [5]; G Floris [6]; K Lambein [7]; P Neven [8]; M Berlière [9]; R Salgado [10]; M Chintinne [11]; K Dahan [12]; S Dedeurwaerdere [13]; J De Grève [14]; A de Leener [15]; H Denys [16]; R de Putter [17]; L Desmyter [18]; M Baldewijns [19]; D Feret [20]; C Fontaine [21]; C Galant [22]; P Hilbert [23]; J Janssens [24]; D Larsimont [25]; P Lefesvre [26]; T Sticca [27]; MD Tkint de Roodenbeke [28]; I Vanden Bempt [29]; C Van den Broeck [30]; I Vandernoot [31]; C Sotiriou [32]; J Van Dorpe [33]; H Antoine-Poirel [34]; Els Van Valckenborgh [35]; Gordana Raicevic [36]; Marc Van den Bulcke [37]; P Aftimos [38]Keywords
Article written during project(s) :
Abstract:
In order to advise the Federal Government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests, the Commission of Personalized Medicine (ComPerMed) has applied, for the breast tumours, the same methodology as previously applied for the digestive tumours. Meaning, the different molecular tests, represented in the shape of algorithms, are annotated with test levels — which aim to reflect their relevance based on current available data and to define the reimbursement — and are documented with recent literature, guidelines and a brief techn…